Literature DB >> 18418655

Temporary sacral nerve stimulation for treatment of irritable bowel syndrome: a pilot study.

Lilli Lundby1, Klaus Krogh, Steen Buntzen, Søren Laurberg.   

Abstract

PURPOSE: This study was designed to evaluate the effect of temporary sacral nerve stimulation in patients with diarrhea-predominant irritable bowel syndrome.
METHODS: Symptoms of diarrhea-predominant irritable bowel syndrome and disease-specific quality of life was evaluated in six patients before and during percutaneous sacral nerve evaluation test. Primary end points were differences between total irritable bowel syndrome symptom score and total quality of life score before and during stimulation. Secondary end points were differences between the variable domains.
RESULTS: Percutaneous sacral nerve evaluation test was performed in five women and one man (median age, 33 (range, 26-54) years). The irritable bowel syndrome symptom score decreased from 48.9 to 28.3 (P = 0.004). Pain, bloating, and diarrhea were significantly reduced from 7.9, 13.5, and 17.3 to 4.4, 7.2, and 10.6, respectively (P = 0.02, P = 0.01, P = 0.03). The irritable bowel syndrome quality of life score decreased from 99.3 to 59.6 (P = 0.009). Daily activities, emotional distress, eating habits, and fatigue were significantly reduced from 26.9, 22.2, 15.2, and 23.2 to 16.9, 13.3, 8, and 14.4, respectively (P = 0.02, P = 0.02, P = 0.02, P = 0.007). Two weeks after cessation of stimulation, the patients had symptoms as before stimulation.
CONCLUSIONS: Temporary sacral nerve stimulation provides a significant reduction in diarrhea-predominant irritable bowel symptoms and improves quality of life. Further studies with permanent implantation and double-blind crossover ON-and-OFF-stimulation to evaluate the impact of placebo effect are needed.

Entities:  

Mesh:

Year:  2008        PMID: 18418655     DOI: 10.1007/s10350-008-9255-y

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

Review 1.  [Sacral nerve modulation in coloproctology].

Authors:  M Gelos; M Niedergethmann
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

2.  Improvement of bowel dysfunction with sacral neuromodulation for refractory urge urinary incontinence.

Authors:  Bradley C Gill; Mia A Swartz; Raymond R Rackley; Courtenay K Moore; Howard B Goldman; Sandip P Vasavada
Journal:  Int Urogynecol J       Date:  2011-09-09       Impact factor: 2.894

3.  Sympathetic and parasympathetic regulation of rectal motility in rats.

Authors:  Timothy J Ridolfi; Wei-Dong Tong; Toku Takahashi; Lauren Kosinski; Kirk A Ludwig
Journal:  J Gastrointest Surg       Date:  2009-09-16       Impact factor: 3.452

4.  Baseline factors predictive of patient satisfaction with sacral neuromodulation for idiopathic fecal incontinence.

Authors:  Jakob Duelund-Jakobsen; Bart van Wunnik; Steen Buntzen; Lilli Lundby; Søren Laurberg; Cor Baeten
Journal:  Int J Colorectal Dis       Date:  2014-04-18       Impact factor: 2.571

5.  Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group.

Authors:  E Falletto; E Ganio; G Naldini; C Ratto; D F Altomare
Journal:  Tech Coloproctol       Date:  2013-04-06       Impact factor: 3.781

6.  Mechanical colon cleansing device in patients with chronic constipation: An experimental study.

Authors:  Mahdi Alemrajabi; Seyedeh Fahimeh Shojae; Mohammad Moradi; Amin Dehghanian; Amirreza Ehsani; Seyed Soroosh Valinia
Journal:  Med J Islam Repub Iran       Date:  2021-06-30

7.  A randomised, controlled study of small intestinal motility in patients treated with sacral nerve stimulation for irritable bowel syndrome.

Authors:  Janne Fassov; Lilli Lundby; Jonas Worsøe; Steen Buntzen; Søren Laurberg; Klaus Krogh
Journal:  BMC Gastroenterol       Date:  2014-06-25       Impact factor: 3.067

8.  Treatment of irritable bowel syndrome with a novel colonic irrigation system: a pilot study.

Authors:  H-H Hsu; W-H Leung; G-C Hu
Journal:  Tech Coloproctol       Date:  2016-05-19       Impact factor: 3.781

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.